A role for Mg 2+ in the pathophysiology of hypertension has been supported for many years. [1] [2] [3] Hypertensive patients were shown to have an impaired intracellular ion content, charac terized by decreased intracellular Mg 2+ and increased intra cellular Ca 2+ and Na + compared to healthy controls. 4 In many crosssectional studies, an inverse correlation between serum Mg 2+ levels and systolic (SBP) and diastolic blood pressure (DBP) was observed, 5 while large longitudinal studies showed that low dietary Mg 2+ intake was also associated with an increased risk for developing hypertension. 6, 7 Several human studies 8,9 investigating effects of oral Mg 2+ supplementation on office blood pressure (BP), along with two recent metaanalyses 10,11 on the field gave contradic tory results. In addition, studies using ambulatory BP moni toring (ABPM) to assess the potential BPlowering effects of Mg 2+ supplementation are extremely few, 12,13 although ABPM has many advantages over the conventional office BP measurement 14 and has been reported to provide more accu rate information concerning the efficacy of the nonpharma cological treatment of hypertension. 15 Furthermore, intracellular Mg 2+ has a regulating role on the activity of major cellmembrane cation channels; 16 in this context, some data support that there may be a link between changes in intracellular ion content induced by Mg 2+ supple mentation and its BPlowering effects. 17, 18 However, none of the Mg 2+ supplementation intervention studies using ABPM included measurement of the intracellular ion levels.
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The aim of this study was to investigate the effect of oral Mg 2+ supplementation on 24h BP and intracellular ion status in patients with uncomplicated mild hypertension and the pos sible relations between potential changes in these parameters.
Methods
Participants. A total of 48 subjects were included in the study. All subjects visited for first time the Hypertension Outpatient Clinic of our Department for hypertension of recent onset. All the examinations were conducted according to the Declaration of Helsinki (1989 amendment). The study was approved by the Background Accumulating evidence implicates a role of Mg 2+ in the pathophysiology of essential hypertension. Previous studies evaluating the antihypertensive efficacy of Mg 2+ supplementation gave contradictory results. this study aimed to investigate the effect of oral Mg 2+ supplementation on 24-h blood pressure (bP) and intracellular ion status in patients with mild hypertension.
A total of 48 patients with mild uncomplicated hypertension participated in the study. Among them, 24 subjects were assigned to 600 mg of pidolate Mg 2+ daily in addition to lifestyle recommendations for a 12-week period and another 24 age-and sex-matched controls were only given lifestyle recommendations. At baseline and study-end (12 weeks) ambulatory bP monitoring, determination of serum and intracellular ion levels, and 24-h urinary collections for determination of urinary Mg 2+ were performed in all study subjects.
results
In the Mg 2+ supplementation group, small but significant reductions in mean 24-h systolic and diastolic bP levels were observed, in contrast to control group (−5.6 ± 2.7 vs. −1.3 ± 2.4 mm Hg, P < 0.001 and −2.8 ± 1.8 vs. −1 ± 1.2 mm Hg, P = 0.002, respectively). these effects of Mg 2+ supplementation were consistent in both daytime and night-time periods. Serum Mg 2+ levels and urinary Mg 2+ excretion were significantly increased in the intervention group. Intracellular Mg 2+ and K + levels were also increased, while intracellular ca 2+ and Na + levels were decreased in the intervention group. None of the intracellular ions were significantly changed in the control group. All subjects were originally evaluated at the Hypertension Outpatient Clinic of our department. The initial evaluation included a full medical history, a physical examination and standard laboratory tests. Inclusion criteria were (i) new onset stage I hypertension, diagnosed in three separate visits with a 1week interval between them, according to interna tional guidelines, 19, 20 (ii) low total cardiovascular risk profile, according to guidelines, 20 and (iii) absence of any antihy pertensive medication. Exclusion criteria were (i) stage II or stage III hypertension, defined as SBP >160 mm Hg and DBP >100 mm Hg, (ii) secondary hypertension, (iii) severe con gestive heart failure, (iv) coronary artery disease, (v) chronic kidney disease, (vi) active liver disease, (vii) diabetes mellitus, (viii) history of malignancy, (ix) history of drug and alcohol abuse, and (x) current use of dietary supplements.
The first 26 consecutive outpatients fulfilling the inclusion and exclusion criteria that were willing to receive the Mg 2+ intervention were assigned to receive 600 mg (25 mmol) of pidolate Mg 2+ orally twice a day for 12 weeks, in addition to standard recommendations for lifestyle changes, according to guidelines 19, 20 (intervention group). Among outpatients who fulfilled the inclusion and exclusion criteria, but were not willing to receive the study intervention, another 26 subjects (age and sexmatched) formed the control group; this group was given only standard lifestyle recommendations and was followed for a similar period. Subjects were instructed not to use any overthe counter dietary or other supplements (vitamins, herbs) during the study. Two patients from each study group refused to com plete all the protocol procedures at studyend. Therefore, a total of 48 subjects were included in the final analysis. All subjects provided informed consent prior to enrollment.
Study protocol. Eligible patients came to the Clinical Research Laboratory of our department at 0800 hours, after a 12h fast. In each subject, body weight and height were measured and body mass index was calculated as weight divided by height squared. Blood samples were drawn for standard laboratory tests and for determination of intraeryrthrocyte Na + , K + , Ca 2+ , and Mg 2+ levels. On the previous day, patients have performed a 24h uri nary collection to determine the urinary Mg 2+ excretion. After blood sampling, an ambulatory BP monitor and a cuff of appro priate size were fitted and the BP recordings started.
Subjects visited the outpatient clinic every 4 weeks, for BP measurement, physical exam, and standard laboratory tests. Possible sideeffects were searched with questions from a standardized questionnaire. At 12 weeks (3 months) they visited again the Clinical Research Laboratory, where all the above measurements were repeated.
Measurements
Ambulatory BP monitoring: Ambulatory BP was monitored using a Spacelabs 90207 device 21 (Spacelabs Medical, Redmond, WA) at baseline and the end of the study. The ABPM was assessed for 25 h. The data of the first hour were not included in the analysis, and this period was used to enable patients to become comfortable with the equipment. The monitor recorded ambulatory BP three times an hour between 0800 and 2400 hours, and hourly between 2400 and 0800 hours. Readings were used for the analysis only if >80% of measurements were valid with no more than two nonconsecutive day hours (0800-2400 hours) with fewer than two valid readings, and no more than one night hour (2400-0800 hours) without reading. The hypertension thresholds used were 140/90 mm Hg for daytime and 125/75 mm Hg for night time. 14 Mean SBP, DBP, mean BP, systolic and diastolic loads were calculated.
Intracellular Na + , K + , Ca 2+ , and Mg 2+ measurement: The prepa ration of the erythrocyte suspensions for the measurement of intracellular Na + and K + was done as follows. Fresh heparinized blood was centrifuged within 1 h of collection. The plasma, buffy coat, and the topmost layer (=10%) of the erythrocytes were discarded, and the remaining erythrocytes were resuspended in icecold isotonic MgCl 2 , pH 7.4. During each of the washes that followed, the supernatant MgCl 2 and the topmost layer of erythrocytes were discarded. The precise hematocrit of the washed erythrocyte suspension was determined in triplicate. The Smith and Samuels method 22 was used for the measure ment of intracellular Na + and K + concentrations. That is to say, an erythrocyte suspension of known volume (0.2 ml) was lysed, diluted with distilled water diluent 9.8 ml for Na + determina tion and 99.8 ml for K + determination, and the cation contents were determined by a flame photometer (Eppendorf type) and calculated as millimoles per liter of erythrocytes (mmol/l).
For the measurement of intracellular Ca 2+ and Mg 2+ , blood was collected via a vein catheter in heparinized polyethylene tubes and centrifuged at 3,000 rpm for 5 min. The plasma, buffy coat, and the topmost layer (=10%) of the erythrocytes were discarded, and the remaining erythrocytes were washed four times in an isotonic phosphatebuffered salineglucose (20 mmol/l phosphate/150 mmol/l NaCl/2 mg/ml glucose, pH 7.4) buffer. For intracellular Ca 2+ , the packed cells were diluted with five volumes trichloroacetic acid 10%, which con tained 20,000 parts of lanthanum chloride. The solution was centrifuged again and the topmost layer was used for the assessment of intracellular Ca 2+ with an atomic absorption spectrophotometer (503 A; PerkinElmer, Waltham, MA). For intracellular Mg 2+ , 1 ml packed red cells was diluted in 19 ml of deionized water. The red cells were then lysed by stirring and refrigerated at 0 °C for 20 min. The cells were subsequently left at room temperature for 20 min and stirred, and refrigerated again until all cells were lysed. A total of 2 ml of SrCl 2 2.5% was added to 5 ml of the hemolysate and 13 ml of deionized water. Intracellular Mg 2+ was measured in the solution with an atomic absorption spectrophotometer (Perkin Elmer 503 A).
Statistical analysis. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 13.0 for windows XP (SPSS, Chicago, IL). Continuous variables were expressed as mean ± s.d. Baseline differences between articles Magnesium Supplementation Effect on Ambulatory BP the two study groups were evaluated with paired ttests or χ 2 tests. For comparisons between the baseline and the end of the study in each study group, paired ttests or Wilcoxon's Signed Rank tests were used according to the normality of the distribution. Betweengroup differences were compared using unpaired ttests or Mann-Whitney Utests where appropriate.
To identify possible relationships between the changes in the parameters under study, bivariate correlation coefficients (r) were calculated using the Pearson's product formula. A P value level <0.05 (twotailed) was considered statistically significant.
results
Baseline demographic characteristics and baseline mean 24h SBP and DBP levels for the Mg 2+ supplementation and the control groups are presented in Table 1 . There were no sig nificant differences between groups in age, body weight, body mass index, serum electrolytes, and other standard biochemical parameters. In addition, the baseline mean 24h SBP and DBP values did not differ significantly between the two study groups.
A shown in Table 2 , in the group of oral Mg 2+ supplemen tation small but significant reductions in mean 24h SBP, DBP, mean BP, systolic and diastolic loads were evident between base line and the end of the study. All these parameters were signifi cantly decreased at the end of the study for both daytime and nighttime periods. In contrast, in the control group, nonsig nificant changes between baseline and the end of the study were observed. Overall 24h changes between baseline and 12 weeks in the Mg supplementation and control groups were −5.6 ± 2.7 mm Hg vs. −1.3 ± 2.4 mm Hg (P < 0.001) for SBP and −2.8 ± 1.8 mm Hg vs. −1.0 ± 1.2 mm Hg (P = 0.002) for DBP.
At the end of the study, a significant increase in serum Mg 2+ levels as well as in 24h urinary Mg 2+ excretion was observed in the intervention group, whereas, nonsignificant changes were evident in the control group ( Table 3) . Among other serum electrolytes, the only significant change was a reduc tion in the serum K + levels in the intervention group. As far as intracellular ion levels were concerned, there was a significant increase compared to baseline in the intracellular Mg 2+ and K + levels in the intervention group. On the contrary, intracellu lar Ca 2+ and Na + levels were significantly decreased at the end of the study. None of the intracellular ions were significantly changed in the control group during the 12week followup period ( Table 3) . Correlation analysis revealed weaktomoderate nonsignifi cant associations between the changes in 24h SBP and DBP and the changes in the serum and intracellular ion levels in the intervention group (data not shown).
During the 12week followup period, in the group of Mg 2+ supplementation one patient reported an episode of mild nausea, and one patient mild diarrheic symptoms (three episodes of mild diarrhea within a day); none of these events led to discontinuation of Mg 2+ intervention. In the control group, one patient reported two episodes of mild diarrhea.
discussion
This study aimed to evaluate the effect of oral Mg 2+ supple mentation for a 12week period on 24h BP and intracellular ion levels in patients with uncomplicated mild hypertension. The main finding was that oral Mg 2+ supplementation was associated with small but statistically significant reductions in the mean 24h SBP, DBP, mean BP, systolic and diastolic loads. All these reductions were consistent in both daytime and nighttime periods. In addition, significant increases in serum Mg 2+ levels and 24h urinary Mg 2+ excretion were evident at the end of the study in the intervention group. Oral Mg 2+ sup plementation was also associated with a significant increase in the intracellular Mg 2+ levels along with a parallel significant fall in the intracellular Ca 2+ and Na + concentrations, tending in this way to revert the abnormalities in the intracellular ion content that characterize patients with hypertension.
Findings deriving from previous studies on the field using casual office BP recordings are contradictory. In several stud ies a BP reduction after oral magnesium supplementation was reported, 8, 18 but other studies failed to confirm these findings. 9, 23 This inconsistence can be partially attributed to the heterogeneity across the studies concerning their clinical design, the dose and the type of Mg 2+ supplement used, the duration of the intervention, the presence and the severity of hypertension of participants at baseline. A pooled estimate of the overall treatment effect of oral Mg 2+ supplementa tion on BP was provided by two recently published meta analyses. The first 10 included 20 studies (including 1,220 subjects), 14 of which in hypertensives and showed that oral Mg 2+ supplementation provided only an 0.6/0.8 mm Hg aver age fall in SBP and DBP. The second 11 metaanalysis included 12 randomized controlled trials involving 545 hypertensive participants. The analysis showed that oral Mg 2+ supplemen tation as compared to control significantly reduced DBP by 2.2 mm Hg, but the respective fall in SBP (−1.3 mm Hg) was nonsignificant.
The first study to investigate the effect of oral Mg 2+ supple mentation on 24h BP showed a reduction of about 5 mm Hg in the averaged mean BP in 25 patients with mild hyperten sion. 12 However, the Mg 2+ supplementation period in this study was only 2 weeks. In a subsequent crossover study by Kawano et al. 13 in 60 patients with mildtomoderate hyper tension, Mg 2+ supplementation produced a 2.5/1.4 mm Hg decline in 24h SBP and DBP after 8 weeks. These beneficial effects were not confirmed in another study in which 300 normotensive women from the Nurse Health Study II were randomized in K + supplementation (40 mmol/day), Ca 2+ supplementation (30 mmol/day), Mg 2+ supplementation (14 mmol/day), all three minerals together or placebo for 25 and strongly related to the baseline BP levels. 13 Our study expands the previous find ings on a beneficial effect of Mg 2+ supplementation on ambu latory BP, showing that a medium dose of Mg 2+ supplement in hypertensive patients has a mild hypotensive effect that is consistent throughout the 24h period. Despite the extensive clinical and experimental research on the field, several aspects concerning the exact mechanisms through which Mg 2+ exerts its BPlowering effects still remain unclear. Among the different mechanisms proposed, a pivotal role could be attributed to the effects Mg 2+ on vascular smooth muscle cell tone, reactivity and contractility. 1, 2, 26 In vascular smooth muscle cells, Mg 2+ acts extracellularly by inhibiting transmembrane Ca 2+ transport and Ca 2+ entry or intracellu larly as a Ca 2+ antagonist, thereby modulating the vasocon striction action of increased intracellular Ca 2+ (refs. 2,16,26) . Further, the influence of Mg 2+ on vascular tone and reactiv ity could also be mediated through its action on Na/K ATPase activity, which regulates the transmembrane Na + and K + transport. 2, 16, 26 In our study, oral Mg 2+ supplementation was associated with a statistically significant increase in the intracellular Mg 2+ levels along with a significant fall in intracellular Ca 2+ and Na + . These effects on the intracellular ion content are in accord ance with the findings of previous clinical 18 and experimental studies. 17, 27 On the limited studies of the field that investigated ion concentrations, the BP reduction after Mg 2+ supplemen tation exhibited mild correlations with the reduction in the intraeryrthrocyte Na +18 or with the increase in serum Mg 2+ levels. 13 In our study, several mild correlations between the observed changes in mean 24h SBP and DBP levels and the changes in serum and intracellular ion concentrations in the intervention group were evident, none of which was sig nificant, possibly due to the sample size. However, the changes in the intracellular ion content we observed support the fact that reversion of the impaired intracellular ion homeostasis is perhaps the basic mechanism through which Mg 2+ exerts its BPlowering effects.
Despite that our findings were based on the most reliable method for measuring BP (that is ABPM) and the laborious methods for intracellular ion measurement, our study has some limitations that should be acknowledged. First, it did not follow a randomized design. However, the controls were very carefully matched to the intervention group. Second, the con trol group did not receive placebo and remained only on life style counseling. To what extent this influenced our findings is unknown, but we have reasons to believe that this had a mini mal impact, as ambulatory BP recordings are not influenced by the placebo effect. 28 Finally, although the followup period of our study is the longest among studies on hypertensive patients using ABPM, it is restricted only to 12 weeks; thus our findings should be confirmed in longer studies.
In conclusion, the results of this study expand the existing evidence for a mild 24h BPlowering effect of oral Mg 2+ administration in patients with mild hypertension. Further, in this study Mg 2+ supplementation was associated with several changes in the intracellular ion content that could repre sent a plausible mechanistic explanation of the hypotensive effect of Mg 2+ . Future longterm clinical trials are required to fully elucidate the exact clinical significance of dietary Mg 2+ supplementation in the management of essential hypertension.
